Coagulation and innate immunity are linked evolutionary processes that orchestrate the host defence against invading pathogens and injury. The complement system is integral to innate immunity and shares numerous interactions with components of the haemostatic pathway, helping to maintain physiological equilibrium. The term 'immunothrombosis' was introduced in 2013 to embrace this process, and has become an area of much recent interest. What is less apparent in the literature however is an appreciation of the clinical manifestations of the coagulation-complement interaction and the consequences of dysregulation of either system, as seen in many inflammatory and thrombotic disease states, such as sepsis, trauma, atherosclerosis, antiphospholipid syndrome (APS), paroxysmal nocturnal haemoglobinuria (PNH) and some thrombotic microangiopathies to name a few. The growing appreciation of this immunothrombotic phenomenon will foster the drive for novel therapies in these disease states, including anticoagulants as immunomodulators and targeted molecular therapies.
The intimate interaction and co-evolution of the haemostatic system together with inflammation and innate immunity is widely appreciated. Blood clot formation is a prime example of the innate immunity's efforts to minimize infection, an inherent complication of wounds and injuries. In addition, there are the well-described changes in the inflammatory response in patients with acute ischaemic cerebrovascular stroke and acute myocardial infarction (Anrather & Iadecola, 2016; Horvath et al, 2016) . Similarly, many invading bacteria have evolved a means to combat host defences by generating antithrombotic and pro-fibrinolytic enzymes to remove restrictive thrombi and achieve pathogen dissemination in the host. Beta-haemolytic group A, C and G Streptococci for example, express streptokinase specific for human plasminogen (Sun et al, 2004; Bergmann & Hammerschmidt, 2007; Engelmann & Massberg, 2013) . Plasmin is generated albeit via a unique mechanism, but nonetheless results in the dissolution of fibrin: breaking down the physical barrier created by the host to sequester and isolate such organisms in times of infection.
Conversely, infection is a known risk factor for thrombosis, but this is likely to be a host response to entrap bacteria to limit infection. The host responds to bacterial pathogens by activating numerous cellular components of the innate immune system, inducing pro-inflammatory cytokines while also promoting a pro-thrombotic state by up-regulating the expression of tissue factor (Opal & Esmon, 2003; Delvaeye & Conway, 2009 ). This inflammatory cycle continues to amplify and sustain tissue factor expression, creating an important link between inflammation and coagulation. This relationship is further reinforced by recent studies demonstrating the association between neutrophil activation and release of neutrophil extracellular traps (NETs), a process coined NETosis, in acute infection and pathologic venous thrombosis (Kimball et al, 2016) .
The above observations have supported the integrated and highly complex function of the haemostatic system, innate immunity and inflammation, which sees them intertwined in a fluidic, global process to achieve host haemostatic equilibrium and immune defence. While this is now widely appreciated in the field, a critically important link between all these processes is provided by the complement system.
Complement is the humoral backbone of the innate immune system. It opsonises bacteria to enhance phagocytosis and pathogen clearance by host cellular responses, thus, 'complementing' the antibacterial activity of antibodies and deriving its nomenclature (Janeway, 2001) . The complement system has also been closely linked to coagulation and fibrinolysis (Amara et al, 2010; Foley, 2016; Foley et al, 2016) . In fact, these systems can be viewed as two evolutionary cascades derived from common ancestral pathways composed of serine proteases with similar structural characteristics (Amara et al, 2010; Wiegner et al, 2016) . Indeed, ancestral forms of coagulation factors including tissue factor, factor VII (FVII), factor X (FX), protein C, prothrombin and fibrinogen exist in jawless vertebrates (hagfish and lamprey) (Davidson et al, 2003) . It was initially thought that only a limited repertoire of complement factors (C1) existed in these species (Kimura et al, 2009) . However, more recent data indicate that the ancestors to the modern complement components (including C3, C4 and C5) originated in the Precambrian period, given identification of ancestral complement components in soft coral and in the horseshoe crab, a 200 million year old representative of arthropods (Dishaw et al, 2005) . Interestingly, this crab activates an integrated coagulation-complement cascade to combat infection and prevent haemorrhage from wounds. Furthermore, extensive gene studies on complement and coagulation proteins in mammals and vertebrates suggest mechanisms of exon shuffling and gene duplications to be responsible in their evolution. Indeed, the first kringle domain of prothrombin seems to have been derived from plasminogen, the central component of the fibrinolytic system, suggesting that the primordial plasminogen kringle predated prothrombin (Patthy, 1985; Kimura et al, 2009) . Hence, coagulation, complement and the fibrinolysis systems evolved hand-in-hand.
What remains unchartered is the clinical significance of these interactions and the potential result of augmenting such a process. What is the clinical manifestation of complement activation in states of excessive coagulation and fibrinolysis, as occurs in trauma, sepsis, surgery and malignancy? If it provides a physiologically protective inflammatory and immune response, is there a threshold after which this becomes detrimental to the host? In the same sense, what are the potential immune and non-immune consequences of hindering this process, for example with anticoagulants and complement inhibitors? This review aims to explore the interactions between the haemostatic and complement systems, and their potential clinical impact.
Coagulation and haemostasis
The major activator of the 'extrinsic' coagulation pathway is tissue factor, which combines with FVII to initiate this cascade. Tissue factor is predominantly located within sub endothelial cells and vessel walls. Given that exposure of tissue factor occurs following the disruption of vessel wall integrity, the extrinsic pathway is generally viewed as being activated by 'external' pathology, such as trauma and vessel injury. Furthermore, monocytes and macrophages are also an important source of tissue factor in the setting of sepsis, providing another link between coagulation and innate immunity (Bode & Mackman, 2014) . The tremendous host inflammatory response to infective pathogens drives this aberrant tissue factor expression, causing massive thrombin generation and fibrin deposition, a key contributor to the hypercoagulability and disseminated intravascular coagulation (DIC) often seen in this context (Egorina et al, 2011; Semeraro et al, 2015; Levi & Van Der Poll, 2017 ). In contrast, the 'intrinsic' or the 'contact activation pathway' is activated by the formation of a complex of high molecular weight kininogen (HMWK), prekallikrein and factor XII (FXII) on collagen, resulting in the activation of coagulation. The intrinsic pathway can be thought of as playing a smaller role in coagulation initiation, as reflected by the clinically asymptomatic nature of individuals with FXII deficiency. However, its role in thrombo-inflammation is increasingly being recognised and will be discussed later in the review.
Thrombin that is generated from the above coagulation pathways drives the conversion of fibrinogen to fibrin. Crosslinked fibrin, the major end product of the coagulation cascade, ultimately forms the fibrin clot: an adhesive localised barrier 'cementing' the site of primary vascular injury initiating coagulation in the first instance.
Innate immunity
The concept of innate immunity and its properties has been explored for over a century. An early lecture paper by Metschnikoff published in the British Medical Journal 125 years ago discusses 'Phagocytosis and Immunity', referring to 'fixed' phagocytes (endothelial cells) and 'free' phagocytes (leucocytes) working together to contain bacterial pathogens. He clearly surmises however, that these are not the only effectors of innate immunity, alluding to many other synergistic mechanisms that may also play a role (Metschnikoff, 1891) . In the decades to follow, the intricacies of the innate immune system have been characterized and refined to provide a comprehensive picture of the host's immediate non-specific defence against invading pathogens and insults. These range from physical barriers, such as skin and mucous membranes, to macrophages, immunoglobulins and varied cellular and cytokine responses (Janeway, 2001) As mentioned earlier, an important constituent of the innate immune defence is the complement system. This process opsonises bacteria and danger-associated molecular patterns (DAMPs) of invading pathogens by antibodies and soluble plasma proteins, facilitating enhanced pathogen killing by host cellular responses (Janeway, 2001; Delvaeye & Conway, 2009 ). The complement system can be activated via three traditional pathways (Fig 1) . The classical pathway (antigen: antibody complexes on pathogen surfaces), binding lectin pathway (binding of mannan-binding lectin, a serum protein, to mannose-containing carbohydrates on the surface of bacteria or viruses) and the constitutively active alternative pathway (initiated when a spontaneously activated complement component binds to the pathogen surface). Each pathway, despite the different mechanisms of activation, ultimately converges to generate the central protease C3 convertase. C3 convertase has further downstream actions; generating the potent anaphylatoxins C3a and C5a as well as the membrane attack complex (MAC), C5b-9, which serve pivotal roles in inflammation and the creation of transmembrane channels within infected cellular membranes leading to cell lysis and death respectively (Janeway, 2001) .
To highlight the close interaction between innate immunity and coagulation, a fourth pathway has also been described, where thrombin cleaves and activates C5 to C5a independently of C3 convertase (Fig 1) (Huber-Lang et al, 2006; Delvaeye & Conway, 2009; Amara et al, 2010) . To exemplify this concept further, Engelmann and Massberg (2013) by thrombosis in immune defence under certain circumstances. This review clearly differentiates haemostasis and thrombosis as being separate entities. Haemostasis is described as the normal physiological process designed to prevent bleeding following vessel injury mediated by the activation of coagulation pathways and platelets, while thrombosis, is deemed a 'pathological deviation of haemostasis', also involving similar activation of platelets and coagulation. However, it is thrombosis and 'thrombosis related signatures' that involve active recruitment and participation of innate immune cells, especially monocytes, neutrophils and dendritic cells, all collaborating to propagate fibrin clot formation, platelet activation and resultant inflammation. This intrinsic mechanism of innate immunity ('immunothrombosis') was characterised by the authors as being an independent, crucial line of host defence and intravascular immunity. Key properties of immunothrombosis involve cell-specific prothrombotic pathways inherent to innate immune cells operating within intact vessels to protect the host from nonself pathogens or antigens. In response to certain agonists, monocytes and their microvesicles express activated intravascular tissue factor that then initiates the extrinsic pathway of coagulation. Another important aspect of immunothrombosis is the increasingly recognized entity of NETs. These are complexes of neutrophil DNA and histones causing a multitude of immunothrombotic sequelae. NETs can directly activate FXII of the contact pathway of coagulation as well as tissue factor, to initiate the 'extrinsic' coagulation cascade. NETs also bind to von Willebrand factor (VWF), a long multimeric glycoprotein produced and secreted by the Weibel-Palade bodies in endothelial cells, platelets and subendothelial connective tissue, which serves to ensnare platelets leading to their aggregation and platelet plug formation. Specific histones present in NETs, namely H3 and H4, not only directly trigger platelet activation, but also behave as DAMPs, activating complement pathways (Semeraro et al, 2011; Silk et al, 2017) . NETs can also locally concentrate enzymes, such as neutrophil elastase, cathepsin G and myeloperoxidase, which not only promote intravascular thrombus growth but can also cleave endogenous anticoagulants, tissue factor pathway inhibitor (TFPI) and thrombomodulin, thus resulting in a hypercoagulable state (Massberg et al, 2010; Engelmann & Massberg, 2013; Esmon, 2013) .
Effects of coagulation on complement activation and regulation
The role of the complement system in coagulation, immunity and 'immunothrombosis' is becoming increasingly appreciated, with an expanding body of literature exploring the links between coagulation and complement activation. A number of thrombosis-related potential complement activators have been studied, including thrombin, plasmin, damaged endothelium, DNA and neutrophil elastase to list a few popular contenders (Foley, 2016) . The relationship between plasmin and complement was, in fact, alluded to back in 1967 by Peter Ward who reported that the plasmin-split fragment of C3 had significant chemotactic potential on polymorphonuclear (PMN) cells. He found that when human plasmin was incubated with human or rabbit C3, a chemotactic factor was generated. This factor was chemotactic for rabbit PMN cells in vitro, caused accumulation of PMN cells in vivo and increased vascular permeability in rat skin (Ward, 1967) . His observations may indeed be describing the properties of the potent anaphylatoxin C3a, which are well appreciated today, and touch on one aspect of coagulation and complement interaction. Thrombin has also attracted much attention, appearing to directly activate C3 and also C5, independently of C3 convertase, thus introducing the concept of an additional pathway of complement activation, as mentioned previously (Huber-Lang et al, 2006) . However, thrombin's cleavage of C5 appears sub-optimal compared to its robustness in cleaving its classical coagulation substrates (i.e. fibrinogen, factors V, VIII, X etc.). This is evident in the supra-physiological concentrations of thrombin often utilised in these studies to achieve detectable amounts of complement cleavage products (Amara et al, 2010; Krisinger et al, 2012; Foley et al, 2016) . One of these studies also failed to demonstrate a correlation between thrombin-antithrombin complex levels and C5a when using a mouse model of inferior vena cava stasis-induced venous thrombosis. These findings hint at the significant but perhaps quantitatively small impact of thrombin in complement cleavage. In addition to thrombin, activated factors XI (FXIa), X (FXa), IX (FIXa) and plasmin have also been found in some studies to effectively cleave C3 and C5 to its active components in in vitro and in vivo murine models. Several of these groups identified FXa and plasmin as the more potent drivers of complement cleavage in this context (Amara et al, 2010; Foley et al, 2016) . In fact, plasmin appears to drive the generation of C5a in thrombosis with similar efficiency to that of some C5 convertases (Foley, 2016; Foley et al, 2016) . These findings suggest that the effects of thrombin in complement activation may actually be due to the activity of plasmin being generated downstream by thrombin itself. As these findings continue to provide an exciting insight into the coagulation-complement interplay, further in vivo studies are paramount to extrapolate this information to the clinical setting.
The complement cleavage products following activation by coagulation factors have also been shown to exhibit robust chemo-attractive properties to human mast cells and neutrophils, highlighting the pro-inflammatory effects of complement cleavage products despite the different methods of activation. Interestingly, but not surprisingly, one study found that FXa-induced cleavage of C3 was significantly suppressed in the presence of a selective FXa inhibitor, Fondaparinux and Enoxaparin, in a concentration-dependent manner, highlighting possible anti-inflammatory effect of such agents in these settings (Amara et al, 2010) .
Coagulation FXII is also recognized as playing an important role in 'immunothrombosis'. Although traditionally perceived as a dispensable coagulation protein, activated FXII (FXIIa) initiates several pro-inflammatory effects via contact pathway activation, showcasing another unique link between coagulation and inflammation (Fig 2) . Some elements known to activate FXII contact pathway include mast cell-derived heparin, misfolded proteins and collagen, and nucleic acids (RNA and DNA) (Nickel et al, 2017) . The role of platelet polyphosphates potentially activating the FXII contact pathway has recently gained significant attention, however, this mechanism remains controversial (Faxalv et al, 2013; Mitchell et al, 2016; Gajsiewicz et al, 2017) . Contact pathway activation then contributes to inflammation through activation of the bradykinin-producing kallikrein-kinin system. The potential protective traits of FXII deficiency is showcased by Thomas Renne and his team using F12 /À (also termed FXII /À ) mice. These mice exhibit potent thromboprotective features in the setting of vessel injury and models of atherosclerosis while infusion of human FXII results in the restoration of thrombus formation (Renne et al, 2005) . Together with the silent clinical nature of FXII deficiency from a haemostatic point of view, there is a growing body of research in the area of selective FXII/FXIIa inhibition to reduce inflammation and pathological thrombosis without increasing the risk of bleeding (Long et al, 2016; Nickel et al, 2017) . There are several notable links between the contact pathway and complement, which include kallikrein, gC1qR protein and C1 esterase inhibitor (C1-INH) (Fig 2) . Activated FXII causes conversion of prekallikrein to kallikrein, which in turn drives further FXII activation and also cleaves HMWK, generating bradykinin. Kallikrein is also involved in the cleavage of several complement proteins including C3, C5 and factor B (Conway, 2015) . The multi-ligand binding protein gC1qR was first identified as a cell surface receptor for C1q, however, it was also found to be a major high affinity receptor for HMWK and FXII (Herwald et al, 1996; Ghebrehiwet et al, 2006) . The ability of gC1qR to directly activate the classical complement pathway by binding C1q and also the kallikrein-kinin-bradykinin system by binding HMWK and FXII, enables it to effectively drive thromboinflammation and generate vasoactive molecules. The two binding ligands of gC1qR (HMWK and C1q) are co-localised on activated endothelial cells and inflammatory tissue, thus showcasing the potential inflammatory and thrombogenic properties of several disease states including atherosclerosis, malignancy and angioedema (Peerschke et al, 2004; . In contrast, C1-INH is a potent inhibitor of the classical complement pathway and also a major regulator of the kinin system, neutralizing the effects of FXIIa, FXIa, kallikrein and HMWK-prekallikrein complexes (Conway, 2015; Intimate relationship between the contact pathway, complement and inflammation. Activated FXII, which is part of the contact pathway of coagulation, also causes conversion of prekallikrein to kallikrein, which in turn drives further FXII activation. Kallikrein not only cleaves HMWK, generating bradykinin, but also cleaves several complement proteins including C3, C5 and factor B. gC1qR is a multi-ligand binding protein with high affinity for HMWK and FXII. Binding of gC1qR to C1q activates the classical complement pathway, while binding to HMWK and FXII activates the kallikrein-kinin-bradykinin system. C1-INH is a potent inhibitor of the classical complement pathway as well as a major regulator of the kinin system neutralising the effects of FXIIa, FXIa, kallikrein and HMWK-prekallikrein complexes. C1-INH, C1 esterase inhibitor; CP, classical pathway; FB, factor B; FXIa, activated Factor XI; FXIIa, activated Factor XII; HMWK, high molecular weight kininogen; LP, lectin pathway; MASP, mannose-associated serine protease.
Platelets also play an integral role in the cross-talk between coagulation and complement in addition to their vital role in primary clot formation and propagation. Platelets have specially evolved anti-microbial properties that can directly interact with innate immunity while also harbouring many pattern recognition receptors. This includes components of the lipopolysaccharide receptor complex that can bind bacterial pathogens and present these to appropriate cells of the innate immune system (Verschoor et al, 2011; Engelmann & Massberg, 2013) . This is shown in recent studies describing mechanisms of platelet glycoprotein (GP)1b and complement C3 cooperation to transport systemic bacteria to splenic CD8a+ dendritic cells in mice (Verschoor et al, 2011) . This process appears essential for the induction of the adaptive immune response as well as attempting to maintain sterility of the circulation in the setting of bacteraemia (Verschoor et al, 2011) .
In addition to roles in antigen presentation and processing, platelet components, similar to coagulation factor proteases, can also directly activate the complement cascade. Chondroitin sulfate A (CS-A), released from platelet alpha granules during platelet activation, is a potent activator of complement in the fluid phase, generating anaphylatoxins, inflammatory mediators and leucocyte activation. Similarly, platelet-bound C3 appears to act as a ligand for leucocyte CR1 (CD35), potentially encouraging platelet-leucocyte interactions (Hamad et al, 2008 (Hamad et al, , 2012 .
Effects of complement cleavage products on coagulation
As mentioned earlier by the concept of 'immunothrombosis', several cells of innate immunity including monocytes and neutrophils are potent effectors of thrombosis (Engelmann & Massberg, 2013) . Similarly, complement proteins play a notable role in this framework of cross-activation. C3a and C5 cleavage products (C5a and C5b) not only form the terminal MAC leading to cell lysis, but collectively influence many aspects of coagulation (Fig 3) . This includes the activation of platelets, induction of tissue factor expression, activation of endothelial cells resulting in the secretion of VWF as well as enhanced exposure of P-selectin, found on activated endothelial cells and platelets (Foreman et al, 1994; Engelmann & Massberg, 2013; Foley, 2016) . Some early studies also demonstrated that C5b-9 (MAC) is capable of enhancing the exposure of prothrombinase assembly sites on the platelet surface by promoting the secretion of platelet factor V (FV) and assembly of the functional FXa/FVa complex, thus providing sites for thrombin propagation (Wiedmer et al, 1986; Hamilton et al, 1990) . Many of these pro-coagulant effects are clinically apparent in disorders of complement dysregulation, such as paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS), where macrovascular and microvascular thrombi cause significant morbidity and mortality (Noris & Remuzzi, 2009; Hill et al, 2013; Jokiranta, 2017) . C5 inhibition in these disorders with the monoclonal antibody, Eculizumab, significantly ameliorates thrombotic disease, further reinforcing the potent procoagulant effects of C5 (Weitz et al, 2012; Hill et al, 2013) . This link is also seen in models of bacterial sepsis and antiphospholipid syndrome (APS), both of which are discussed later in this review.
Important components of the lectin pathway (LP) of complement activation are the serine protease pattern recognition molecules: Mannose-associated serine protease 1 (MASP-1) and 2 (MASP-2). MASP-1 is the key initiator protease of the
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Anaphylatoxin The dual effects of important complement proteins. C3a and C5 cleavage products (C5a and C5b) not only form the terminal membrane attack complex, leading to cell lysis, but also influence many aspects of coagulation. This includes the activation of platelets, induction of tissue factor expression, activation of endothelial cells resulting in the secretion of von Willebrand factor as well as enhanced exposure of P-selectin found on activated endothelial cells and platelets. The serine protease pattern recognition molecules, mannose-associated serine proteases 1 and 2 (MASP-1, MASP-2) are important components of the lectin complement pathway. MASP-1 is the key initiator protease of the LP while MASP-2 is the main protease cleaving C4 and some C2, to generate C3 convertase. In vitro studies indicate that MASP-2 cleaves prothrombin to thrombin while MASP-1 appears to possess a thrombin-like property, cleaving factor XIII, HMWK, fibrinogen and activating thrombin activatable fibrinolysis inhibitor. HMWK, high molecular weight kininogen; MAC, membrane attack complex; MASP, mannose associated serine protease; TAFI, thrombin activatable fibrinolysis inhibitor; TF, tissue factor; VWF, von Willebrand factor. LP while MASP-2 is the main protease cleaving C4, and some C2, to generate C3 convertase. Further to their role in complement activation, there are indications in vitro that both enzymes also play a significant role in coagulation (Fig 3) (Kozarcanin et al, 2016) . MASP-2 cleaves prothrombin to thrombin while MASP-1 appears to possess a thrombin-like property, cleaving FXIII, HMWK, fibrinogen and activating thrombin activatable fibrinolysis inhibitor (TAFI) (Krarup et al, 2008) . In vivo, MASP-1 appears to be involved in thrombogenesis both in animal models and in human plasma (La Bonte et al, 2012; Jenny et al, 2015) . MASP-1 resembles thrombin both structurally and in terms of substrate specificity and is able to induce coagulation only via the cleavage of prothrombin (Jenny et al, 2015) . Conversely, Kozarcanin et al (2016) also demonstrated that platelet activation followed by fibrin formation during clot formation, leads to the activation of both MASP-1 and MASP-2, further amplifying coagulation as well as inflammation in thrombotic disorders.
Clinical consequences of coagulation and complement co-activation

Sepsis
Severe sepsis leads to immense activation of both the coagulation and complement cascades ( Table I ). The clinical effects of this were shown in a primate model of sepsis-induced multiple organ failure following an Escherichia coli challenge (Silasi-Mansat et al, 2010) . This model demonstrated two distinct stages of sepsis: the first being an exacerbated intravascular host defence response where complement activation leads to opsonisation of bacteria, critical for innate immune defence and pathogen clearance. The second stage follows clearance of the pathogen and reflects an uncontrolled extravascular host recovery response driven by ischaemia-reperfusion injury and harmful effects of complement activation, which eventually leads to end organ dysfunction. A potent C3-targeted complement inhibitor (Compstatin) was found to significantly reduce leucopenia, thrombocytopenia and the accumulation of macrophages and platelets in organs when administered in the second stage (ischaemiareperfusion) of sepsis. Similarly, with regards to coagulation, Compstatin decreased pro-coagulant effects by down-regulating tissue factor, plasminogen activator inhibitor-1 (PAI-1) and fibrin degradation products, while preserving endothelial anticoagulant properties. From a clinical point of view, the intervention also improved overall cardiac, renal and hepatic function. Histological analysis of vital organs collected from animals euthanized after 24 h showed reduced microvascular thrombosis, improved vascular barrier function and less leucocyte infiltration and cell death. These features indicate significant augmentation of organ injury and pro-coagulant effects following complement inhibition during the second stage of severe sepsis (Silasi-Mansat et al, 2010) .
Trauma induced coagulopathy
Coagulation activation, hyperfibrinolysis and consumptive coagulopathy are key pathophysiological mechanisms of trauma-induced coagulopathy (Hayakawa, 2017) . However, there is emerging data highlighting the additional complex interplay between these processes and inflammation and immunity. In particular, recent ex vivo studies suggest that complement activation in trauma patients alters platelet function (Atefi et al, 2016) . Not surprisingly, platelets from trauma patients were found to have significantly higher amounts of complement C3a and C4d on their surface compared with platelets from healthy individuals. Healthy donor platelets incubated with the sera from trauma patients exhibited hypoactivity on platelet aggregometry testing. This occurred despite the platelets having increased agonistinduced calcium flux following exposure to trauma sera. Depletion of complement from trauma sera further reduced activation of these hypoactive platelets. Equally, complement activation increased platelet aggregation. These findings suggest that complement has a profound effect on haemostasis by interfering with platelet activation and function (Atefi et al, 2016) (Table I) .
Systemic lupus erythematosus (SLE)
Complement plays a major role in SLE (Table I ). This multisystem autoimmune disorder often exhibits autoantibodies against DNA and histones (Linnik et al, 2005; Dieker et al, 2016) . These antibodies induce complement activation in addition to the formation of immune complexes that deposit in renal glomeruli, activating the classical complement cascade and resulting in renal injury and lupus nephritis; a major cause of morbidity and mortality in SLE (Leffler et al, 2014; Rother et al, 2017) . Furthermore, genetic C1q deficiency, with impaired classical pathway activation, appears to be a strong genetic risk factor for SLE (Leffler et al, 2014) . Deficiencies and mutations in other classical pathway proteins, including C1r, C1s, C4 and C2, are also associated with an increased risk (Leffler et al, 2014) . Reduced expression of complement inhibitors, such as Factor H and CD46, increases host sensitivity to complement activation and deregulation of immune cells. Cellular debris and microparticles also become opsonised with complement and antibodies hindering their clearance in SLE (Nielsen et al, 2012) . The increased thrombotic risk in SLE is well appreciated, with cardiovascular disease being a major long-term complication (Bazzan et al, 2015) . Complement activation products on platelets may explain the increased risk of venous thrombosis as a result of platelet activation that is also seen in SLE (Lood et al, 2012) . Thrombotic disease is often associated with the presence of antiphospholipid antibodies in APS and associated complement activation.
Given the central role of complement in SLE, recent studies have shown positive results with Eculizumab therapy in (Sciascia et al, 2017) .
Antiphospholipid syndrome
Another disease state where the interplay between coagulation and complement has clinical implications is APS (Table I) . APS is defined by the revised 'Sapporo criteria', which includes the presence of persistent antiphospholipid antibodies (i.e. lupus anticoagulant, anti-cardiolipin antibodies or anti-b2-glycoprotein antibodies) in patients suffering from venous and/or arterial thromboses and/or recurrent fetal loss (Delvaeye & Conway, 2009; Gomez-Puerta & Cervera, 2014) . Several mouse models have demonstrated antiphospholipid-mediated fetal loss to be a complement-driven inflammatory process. Antiphospholipid antibodies appear to bind and activate complement on trophoblasts, leading to C5a generation. C5a then engages the complement receptor C5aR on neutrophils, consequently up-regulating tissue factor expression that results in activation of coagulation as well as inflammation in the decidua with the release of reactive oxygen species (Girardi et al, 2003; Weiler, 2008 ). It appears that tissue factor's inflammatory signalling through the protease-activated receptor 2 (PAR-2, also termed F2RL1) is a critical event, resulting in neutrophil activation, trophoblast injury and fetal death (Redecha et al, 2008) . This is supported by the observation of F2rl1 (PAR-2) À/À knockout mice treated with antiphospholipid exhibiting less neutrophil activation and normal pregnancies. At present, the mainstay of APS treatment during pregnancy is anticoagulation in an attempt to reduce fetal loss. The effectiveness of heparin-based therapy in this context lies in its dual antithrombotic and anti-complement properties (Weiler et al, 1978) . Heparin can bind and inactivate C1, inhibit MAC assembly and also stop the formation of C3 convertase (Almeda et al, 1983; Kulkarni & Afshar-Kharghan, 2008) . Redecha et al (2008) have also demonstrated the ability of Simvastatin and Pravastatin (Hydroxymethylglutaryl-CoA reductase inhibitors used as anti-hyperlipidaemic therapy) to reduce tissue factor and PAR-2 expression on neutrophils and prevent pregnancy loss in this setting, thus blunting the inflammatory as well as the pro-coagulant effects of this disorder.
Autoimmune and alloimmune haemolytic anaemia
Autoimmune haemolytic anaemia (AIHA) is a well-known disorder with a close relationship between coagulation and complement (Table I) . This is most appreciated in cold agglutinin disease (CAD) where IgM antibodies agglutinate red cells, resulting in their destruction. CAD is classified as either primary or secondary. Primary CAD is a clonal B-cell lymphoproliferative disorder while the secondary form is associated with a range of infections and malignancies (Brodsky, 2015) . In both cases, IgM antibodies agglutinate erythrocytes at an optimal temperature of 3-4°C, and potentially higher depending on the thermal amplitude of the antibody (Berentsen, 2016) . These antigen-bound IgM antibodies are potent activators of complement, binding C1q and activating the classical complement cascade. Upon exposure to a higher temperature, the IgM antibodies dissociate from the red cells, allowing the agglutinated cells to separate while leaving behind bound C3b. C3b is then cleaved to C3d resulting in a strongly positive direct antiglobulin test for C3d, however negative for IgM (Berentsen, 2015) . The major mechanism of haemolysis in stable CAD is the extravascular destruction of these C3b-coated erythrocytes by the reticuloendothelial system (Jaffe et al, 1976; Berentsen, 2016) . However some severe cases and acute exacerbations can result in C5-mediated intravascular haemolysis, where C5 inhibition with Eculizumab has been trialled as a therapeutic agent (Roth et al, 2009; Gupta & Wang, 2014) . There is also in vitro evidence supporting a monoclonal antibody targeting C1s that can help control the extravascular haemolysis (Shi et al, 2014; Brodsky, 2015) . Alloimmune haemolysis, seen in haemolytic transfusion reactions, is caused by an immune response to a foreign antigen on the donor's erythrocytes. This leads to -and extravascular haemolysis through several mechanisms, including complement-mediated lysis, phagocytosis of C3b-coated erythrocytes by macrophages or destruction of IgG-covered red (Chen et al, 2009 (Chen et al, , 2015 (Chen et al, , 2017 Excessive AP activation C5a can prime neutrophils for ANCA induced degranulation (Hao et al, 2013 ) Activated platelets can drive complement activation C3a, C3b, C5b-9 ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; AP, Alternate path of complement activation; C1-INH, C1 esterase inhibitor; CP, Classical pathway of complement activation; GPI, glycosylphosphatidylinositol; HMWK, high molecular weight kininogen; IL, interleukin; LP, Lectin Pathway of complement activation; MAC, Membrane attack complex; MASPs, mannose-associated serine proteases; NETs, Neutrophil extracellular traps; PAI-1, plasminogen activator inhibitor-1; TNFa, tumour necrosis factor a; u-PA, urokinase type plasminogen activator.
cells by the reticuloendothelial system (Strobel, 2008) . The resulting production of anaphylatoxins, release of cytokines driving inflammation, contact pathway and kinin system activation and fibrinolysis manifest clinically with a systemic inflammatory response, DIC, bleeding, microvascular disruption with renal failure and shock (Strobel, 2008) . The increased risk of thrombosis in haemolytic anaemia is well recognized, with recent studies quoting a 2Á6-fold higher risk of venous thromboembolism compared to non-AIHA patients (Ungprasert et al, 2015) . Complement-mediated haemolysis plays a central role in driving this thrombogenicity (Chapin et al, 2016) . Erythrocyte lysis results in the exposure of phosphatidylserine and the release of tissue factor-bearing microparticles, both of which activate platelets and coagulation pathways (Zwaal & Schroit, 1997; Zahra et al, 2011; Chapin et al, 2016; Tripisciano et al, 2017) . Circulating free haem can also function as a complement convertase, activating further complement pathways (Frimat et al, 2013) . In addition, haemolysis is well known for its direct effects on endothelial cell injury, vasoconstrictive effects and the release of reactive oxygen species, creating a prothrombotic endothelial surface and impairing vasomotor function (Chapin et al, 2016) .
Disorders of complement regulatory dysfunction
As with all physiological enzymatic cascades, the activation of complement is effectively controlled by a series of soluble and membrane-associated regulatory proteins. Soluble inhibitory complement regulators, including C1 inhibitor, C4 binding protein (C4BP), factor H and factor I, limit complement activation at multiple stages within the cascade. In addition, membrane-bound regulatory proteins, such as complement receptor 1 and glycosylphosphatidylinositol (GPI) anchored proteins (CD55 and CD59) protect cells from complementmediated destruction (Markiewski et al, 2007) . Abnormalities in these regulatory proteins can cause unobstructed complement activation, thrombosis and tissue destruction, which is seen in several notable disorders, including aHUS, PNH and hereditary angioedema (HAE) (Richards et al, 2003; Noris & Remuzzi, 2009; Moore et al, 2010; Csuka et al, 2017; Hill et al, 2017) (Table I) .
Paroxysmal nocturnal haemoglobinuria
Paroxysmal nocturnal haemoglobinuria is an acquired clonal haemopoietic disorder due to a somatic mutation of the Xlinked PIGA gene. This results in a partial or absolute deficiency of all GPI-anchored proteins, leaving many cells vulnerable to unregulated complement-mediated destruction. Intravascular haemolysis is thus a major feature of this disorder. While cytopenias, aplasia and smooth muscle dystonias are all common manifestations of PNH, thrombosis, especially in unusual sites, remains a dreaded complication associated with significant morbidity and mortality (Parker, 2012; Hill et al, 2013 Hill et al, , 2017 . The mechanism of thrombosis in PNH is complex, multifaceted and an area of ongoing research. Platelet activation, complement-mediated haemolysis, vascular toxicity from free haemoglobin, nitric oxide depletion, absence of other GPI-linked protein, such as urokinase-type plasminogen activator receptor, with impairment in fibrinolysis along with overall endothelial dysfunction are all likely to contribute to thrombosis in this disorder (Hill et al, 2013) . Complement activation on cell surfaces results in the formation of the MAC with subsequent cell lysis. Both MAC formation and C5a generation may also induce the expression of tissue factor as well as PAI-1, thus promoting thrombosis and anti-fibrinolysis. The C5a generated further enhances prothrombotic phenomenon through the production of cytokines interleukin (IL) 6, IL8 and tumour necrosis factor-a (TNF-a). Of these, IL6 can promote thrombin generation and may also inhibit ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity, which is vital for VWF cleavage. Overall, a vicious cycle ensues, where thrombosis activates complement that then drives further thrombosis and inflammation (Table I ). The pivotal role of unregulated complement activation in PNH is again clearly demonstrated by the excellent clinical response to C5 inhibition by Eculizumab in these patients, which results in both reduced intravascular haemolysis, cytopenias and, above all, thrombotic complications. This mainstay of PNH therapy has also been found to cause a rapid decrease in plasma tissue factor microparticles, thrombin generation, D-dimers, thrombinantithrombin complexes, plasmin-antiplasmin complexes, IL6 and several markers of endothelial cell activation (i.e. tissue plasminogen activator, VWF, TFPI) (Helley et al, 2010; Weitz et al, 2012) . This biological evidence translates to the clinical benefits of reduced thrombosis following complement inhibition in this disorder (Hill et al, 2013) .
Atypical haemolytic uraemic syndrome
Atypical HUS (aHUS) is a thrombotic microangiopathy resulting from dysregulation of the alternate pathway of complement activation and C3 convertase activity. Implicated mechanisms include mutations in the factor H (CFHR5), factor B (CFB) and I (CFI) genes as well as membrane co-factor proteins (CD46) (Richards et al, 2003; Kavanagh et al, 2005; Moore et al, 2010) . Approximately 5-10% of patients exhibit autoantibodies to factor H as the causative factor for complement dysregulation (Dragon-Durey et al, 2005; Jozsi et al, 2008; Moore et al, 2010) . The disorder is classically seen in the paediatric population, manifesting with characteristic haemolytic anaemia, thrombocytopenia and acute renal failure with significant associated morbidity and mortality. This uncontrolled complement activation results in progressive endothelial cell damage and disruption to the microvasculature, which in turn is a driver of coagulation and thrombotic complications (Table I) . The role of activated platelets in the pathogenesis and propagation of aHUS is underappreciated. Platelets are likely to play a key role because thrombocytopenia is a characteristic feature of this thrombotic microangiopathy and the thrombi in capillaries and arterioles contain platelets (Noris & Remuzzi, 2009) . Platelets are efficiently activated via MAC formation on the platelet membrane or C5a (Conway, 2015) . In addition, platelets are usually protected from complement-mediated destruction by the action of factor H and other membrane regulators (Licht et al, 2009) . As this mechanism is severely compromised in aHUS, as a result of impaired alternative pathway regulation, platelets are subject to unregulated attack. This phenomenon is then likely to result in the thrombocytopenia and production of plateletrich microthrombi seen in this disorder (Jokiranta, 2017) .
Complement inhibition with Eculizumab has proven profoundly efficacious in aHUS resulting in the inhibition of intravascular haemolysis and the related thrombotic microangiopathy, rescue of renal function and contribution to improved prognosis (Zuber et al, 2012; Legendre et al, 2013; Zhang et al, 2017) .
Hereditary angioedema
Another less common but clinically significant disorder illustrating the various areas of interaction among the serine protease cascades is HAE. This condition is characterized by recurrent episodes of oedema as a result of mutations in the genes encoding C1 inhibitor (C1-INH). Although named after its complement inhibitory activity, C1-INH also inhibits proteases of the coagulation, fibrinolytic and kinin pathways, being a vital physiological inhibitor of plasma kallikrein, FXIa and FXIIa. Oedema is therefore deemed secondary to excessive bradykinin production as a result of unregulated activation of the prekallikrein-kallikrein-HMWK-bradykinin system due to C1-INH deficiency or dysfunction (Markiewski et al, 2007) . HAE is thus an excellent example showcasing how genetic alterations in genes encoding complement and coagulation can initiate activation of common pathways, in this case the intrinsic coagulation cascade (Table I) .
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Complement activation appears to play a critical role in the development of ANCA-associated vasculitis (AAV) (Chen et al, 2017) . Despite the defining histological feature of this disorder being minimal deposition of immunoglobulin and complement in the renal glomeruli, accumulating evidence indicates that the alternative pathway of complement activation may actually play a crucial aetiological role. Several studies have identified glomeruli samples of AAV persistently expressing C5b-9, C3d, C3c factor B and Bb, considered to be a marker of alternative pathway activation. Often, evidence of complement activation appears to be associated with a more severe clinical phenotype with a higher proportion of crescents, more severe tubulointerstitial lesions, greater proteinuria and poorer renal function (Chen et al, 2009) .
The development of microthrombi and the resultant thrombotic microangiopathy is also a common feature of this disease, often presenting with more severe renal injury and contributing significantly to its morbidity and mortality (Chen et al, 2015) . Focusing on the interaction between complement and coagulation in this disorder, reduced levels of C3 in serum appear to be associated with reduced renal survival and the presence of renal thrombotic microangiopathy (Chen et al, 2015) .
In vitro studies show that recombinant C5a can prime neutrophils for an ANCA-induced respiratory burst and degranulation (Hao et al, 2013) . Given our prior knowledge, we know that this also leads to the release of tissue factor and NETs, with resultant activation of coagulation and thrombin generation. Furthermore, this combination of activated neutrophils, ANCA and complement systems result in a vicious positive feedback cycle of coagulation, inflammation and AAV development (Table I) . It is therefore not surprising that patients with AAV have a hypercoagulable state and are at high risk of venous thromboembolic disease. The interaction between complement and activated platelets further drives this pro-coagulant state. Activated platelets can initiate the complement system, as seen by increases in C3a generation, C3b deposition and C5b-9 production (Chen et al, 2017) . Given the central role of complement in the development of AAV, selective complement inhibition is being investigated as potential therapy for this disease (Chen et al, 2017) .
Potential immunomodulatory effects of anticoagulation
Given the complex interplay between coagulation, innate immunity and inflammation, the potential impact of anticoagulation on these physiological systems has gained significant interest. Does altering coagulation result in augmentation of inflammation or the immune response?
This relationship was probably most famously and controversially explored in the literature surrounding activated protein C (APC) (Bernard et al, 2001a,b) . Despite a large body of research supporting the use of recombinant APC to restrict an inappropriately activated coagulation and inflammatory cascade in patients with severe sepsis, the drug was eventually withdrawn from clinical use due the increased rates of haemorrhage and overall limited efficacy found in subsequent clinical trials (Abraham et al, 2005; Ranieri et al, 2012; Annane et al, 2013) . It is unlikely however that we have heard the last of APC in this area. Recent data on the anti-inflammatory role of APC includes its potential to inhibit NETosis via an endothelial protein C receptor (EPCR), protease-activated receptor 3 (PAR3) and macrophage-1 antigen (Mac-1) dependent mechanism (Healy et al, 2017) . Interestingly, pre-treatment of neutrophils with APC prior to induction of NETosis also inhibited platelet adhesion to NETs. The authors also used a nonhuman primate model of bacterial sepsis to demonstrate that infusion of APC reduced neutrophil activation in vivo (Healy et al, 2017) .
Along a similar line, recombinant human soluble thrombomodulin is used widely in the management of sepsisinduced DIC in Japan. Emerging reviews in this area suggest benefits in reducing D-dimer levels and improving DIC scores (Yamakawa et al, 2015; Hagiwara et al, 2016) . Whether this translates into a survival benefit, however, needs further investigation.
As mentioned earlier in the review, Amara et al (2010) showed that the presence of selective FXa inhibitors resulted in a significant reduction in FXa-induced cleavage of C3. It is also clear that in some clinical conditions, such as APS, anticoagulation not only reduces thrombosis, but also has additional off target benefits, in this case the prevention of recurrent gestational loss.
Warfarin is an oral vitamin K antagonist which inhibits vitamin K-dependent activation of FII, FVII, FIX, FX and the natural anticoagulants, protein C and protein S. Despite being one of the oldest anticoagulants in use today, literature exploring its effects on immunity is limited. In vitro studies from the late 1980s showed that warfarin inhibits T-lymphocyte activation in a dose-dependent nature. Warfarin was also found to prevent IL2 production, although often with concentrations in excess of therapeutic serum levels (Bruserud & Lundin, 1987) .
Heparin is a naturally occurring glycosaminoglycan of variable polymer length, which inhibits coagulation by binding to and potentiating the action of antithrombin III. It also possesses several anti-inflammatory properties, some of which are independent of its role as an anticoagulant. These include, but are not limited to, the inhibition of function and expression of adhesion molecules, cytokines, angiogenic factors and, of course, complement proteins (Lever et al, 2000; Ludwig, 2009; Zarychanski et al, 2015) . In fact, studies on the effect of heparin in patients with sepsis, severe sepsis, septic shock or DIC associated with infection consider it a safe and feasible intervention, however, evidence to support a reduction in mortality in this context requires further investigation (Jaimes et al, 2009; Zarychanski et al, 2015) . Bobek and Kovarik (2004) extensively reviewed the antitumour and anti-metastatic effects of warfarin and heparins. Anticoagulation-linked inhibition varied from apoptosis induction, inhibition of differentiation, interference with tumour angiogenesis, metastatic processes and also the immune system. Immune system effects of these anticoagulants include the activation of macrophages and natural killer cells, increased TNF and interferon (IFN), increase in the activity of neutrophils and inhibition of the extravasation of leucocytes from vessel walls. Heparins can also interfere with immune reactions by inhibiting the complement system or by enhancing the susceptibility of malignant cells to immunological attacks (Bobek & Kovarik, 2004) .
The last decade has seen the increasing clinical use of novel targeted oral anticoagulants, which include direct thrombin inhibitors (Dabigatran) and anti-FXa agents (Rivaroxaban, Apixaban and Edoxaban). These have been clinically proven to provide non-inferior anti-thrombotic therapy compared to warfarin with often, a more favourable bleeding profile (Connolly et al, 2009; Schulman et al, 2009; The EINSTEIN Investigators, 2010 , 2012 Agnelli et al, 2013; Madan et al, 2016) . The potential immunomodulatory effects of these agents continue to be explored. A recent study with a murine stroke model showed that pre-treatment of these rats with Rivaroxaban attenuated stroke severity by a dual antithrombotic and anti-inflammatory mechanism. Rivaroxaban appeared to dampen the inflammatory response in the ischaemic brain by down-regulating Intercellular Adhesion Molecule 1 expression and the activation of CD68+ cells of the immune system (Dittmeier et al, 2016) .
Rivaroxaban may also be effective in limiting complement activation in patients with APS. A cohort of APS patients with previous venous thromboembolic disease on therapeutic warfarin were randomized to either switch to Rivaroxaban or continue on warfarin. Markers of complement activation were measured at baseline and at day 42 and compared to a group of normal controls. Not surprisingly, APS patients exhibited significantly higher C3a, C5a and terminal attack complexes compared with normal controls at both time points irrespective of the anticoagulation. In the patients randomized to switch to Rivaroxaban, complement activation markers were lower at day 42 compared to those remaining on warfarin (Arachchillage et al, 2016) . Although the authors note no correlations between serum Rivaroxaban levels and complement activation markers, it is clear that Rivaroxaban may provide immunomodulatory benefits to APS patients in addition to its primary anticoagulation role. Further studies are needed to explore the potential reduced thrombo-inflammatory properties of anticoagulants and anti-fibrinolytics in the human body and other disease states.
Role of complement inhibitors
The growing appreciation of the molecular links between coagulation and complement pathways has invigorated the development of targeted complement inhibition in specific disease states (Fig 1, Table II ). At the forefront is Eculizumab (Soliris); a humanised monoclonal antibody against C5 and the cornerstone of therapy for PNH and aHUS, as already discussed (Hill et al, 2017) . However, as previously alluded to, the efficacy of Eculizumab in inhibiting MAC formation sees its therapeutic potential expand to other disorders of unregulated complement activation. Diseases complicated by thrombotic microangiopathy, glomerulonephritides (including lupus nephritis) and severe CAD are some examples where Eculizumab has been trialled (Melis et al, 2015; Sciascia et al, 2017) . Eculizumab's role in reducing thrombosis is evident in PNH and aHUS and further research is required to elucidate whether this also holds true in other pathologies where it may have therapeutic potential (Weitz et al, 2012; Hill et al, 2013) .
Another drug in pre-clinical trials is Compstatin; a cyclic peptide that inhibits complement activation by binding C3 and preventing subsequent C3 cleavage (Mastellos et al, 2015) . Other small molecule monoclonal antibodies in development include IFX-1 (InflaRx), a C5a inhibitor designed for the treatment of septic shock; TNT-009, an inhibitor of C1s and the classical pathway to treat CAD; Lampalizumab, a factor D inhibitor, and Bikaciomab, a factor B inhibitor, both being trialled for the treatment of age-related macular degeneration (Melis et al, 2015; Harris, 2017) . Moreover, several agents operating at a gene expression level are also being developed which include antisense for factor B, RNA interference for C5 and prevention of C6 expression by locked nucleic acid technology (Harris, 2017) .
Conclusion
Our understanding and appreciation of the complex relationship between coagulation, innate immunity and inflammation has clearly advanced. Despite the close evolutionary ties and their capacity to cross activate, many open questions remain. The clinical consequences of these interactions are evident in a variety of pathologies where coagulation and inflammation often appear inseparable. Complement inhibitors are gaining significant attention as their therapeutic role expands to include other disorders with complement dysregulation. Anticoagulation and its potential for immune augmentation in this context is an exciting prospect requiring further delineation. 
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